JENSCARE-B (09877) announced that for the fiscal year ending December 31, 2025, the Group expects to achieve revenue of approximately RMB 90 million to RMB 92 million, alongside other income and gains of approximately RMB 15 million to RMB 18 million, resulting in a total of approximately RMB 105 million to RMB 110 million.

The Group achieved substantial revenue in its very first year of commercialization, primarily attributable to the following factors during the reporting period: 1. The Group's transcatheter aortic valve replacement system, Ken-Valve, generated robust revenue in its inaugural year of commercialization. Ken-Valve is suitable for aortic regurgitation or combined stenosis, and its product design and operational advantages have enabled the procedure to be rapidly adopted across multi-tier medical institutions; 2. The Group conducted fee-based clinical implants for several structural heart interventional products overseas, with their research outcomes and clinical application advantages receiving high praise from key opinion leaders and experts across various continents, addressing the vast, long-unmet clinical needs for structural heart disease globally.

The Group will continue to advance the development of multiple product pipelines and further deepen its international strategic layout in 2026, aiming to achieve high-speed revenue growth.

Furthermore, it will continuously enhance management efficiency and reduce operational costs in areas such as production, supply chain, marketing, and operational management to realize its long-term strategic development goals.